Laminate Medical Technologies today announced it has won FDA breakthrough device designation for its VasQ external support for patients in need of an arteriovenous fistula (AVF) for hemodialysis. Tel Aviv, Israel–based Laminate’s VasQ device is a nitinol external support placed around the artery and vein at the creation site. It is designed to optimize the […]
Baxter (NYSE:BAX) officials apparently think their company can benefit from a Trump administration and CMS proposal to provide extra reimbursement for new and innovative dialysis equipment and supplies. Just days ago, CEO Joe Almeida told analysts in an earnings call that the company planned to invest $500 million to significantly increase production capacity and meet new […]
A Texas federal judge today extended a block on a federal rule that would require dialysis providers to disclose any charitable assistance patients receive to insurers. The indefinite extension was granted by U.S. District Judge Amos Mazzant in Sherman, Texas, in a suit filed by dialysis providers including Fresenius Medical Care (NYSE:FMS), DaVita. The rule, which was announced by […]
Outset Medical, previously Home Dialysis Plus, said it raised $91 million in a new funding round, with $51 million in equity and $40 million in debt funding. Funds are slated to continue development and promotion of its Tablo all-in-one dialysis system. The $51 million round of equity funding was led by new investor Fidelity Research […]
The fundraising continues at Minnesota’s Pursuit Vascular, which has reeled in more than $5.1 million through a new equity offering.
Executives disclosed the new cash infusion in a recent regulatory filing, though specific investors are not mentioned.
Pursuit Vascular said it raise approximately $1.6 million in a debt and securities offering to a group of 33 unnamed investors.
Based in Maple Grove, Minn., Pursuit markets a device called ClearGuard that’s designed to kill bacteria and fungi in hemodialysis catheters. The product, an antimicrobial fluid lock, received FDA approval in late 2013.